7% (44/66) and 42.9% (15/35) were in remission. At M6 remission rates was significantly higher while response rates tended to be higher among biologic-naïve versus biologic-failure CD patients. Conclusions VDZ offers an effective treatment option in real-life settings and treatment effectiveness appears higher in biologic-naïve versus b…[Read more]